Vorinostat

Zolinza (vorinostat) is a small molecule pharmaceutical. Vorinostat was first approved as Zolinza on 2006-10-06. It is used to treat t-cell lymphoma cutaneous in the USA. The pharmaceutical is active against histone deacetylase 1. In addition, it is known to target histone deacetylase 9, histone deacetylase 11, histone deacetylase 3, histone deacetylase 2, histone deacetylase 6, polyamine deacetylase HDAC10, histone deacetylase 5, and histone deacetylase 8. Zolinza's patents are valid until 2028-03-18 (FDA).